Enfuvirtide Manufacturer 159519-65-0 For Peptide Protein CAS NO.159519-65-0

Advantages:
 
Hubei XinRunde Chemical Co., Ltd is a renowned pharmaceutical manufacturer. We can offer high quality products at competitive price in quick delivery with 100% custom pass guaranteed. Never stop striving to offer our best service is our philosophy. We have Flexible and Untraceable payment terms. As a leading manufacture, our products have been exported to Germany, Norway, Poland, Finland, Spain, UK, France, Russia, USA, Brazil, Mexico, Australia, Japan, Korea, Thailand, Indonesia, Uruguay and many other countries.

1. Quality.Every batch of steroid powders have tobetested by our QC(quality control) before they are allowed to sell.

2. Delivery We have stock, so we can delivery quickly at the very day when receive the payment. Within 24 hours after receiving the payment Lead time 4 or 7 days.

3. Discreet package Safelyand Professionally Disguised Package Guaranteed. For your safety and to insure delivery all products will be packed in a discreet way to prevent any suspicions, no steroids related name will appear on the parcels. high successful delivery rate.

4. Warm after-sale service Any of your question would be solved for the first as soon as possible.

1. Quick Details:

Product Name: Enfuvirtide Acetate (T-20)
Sequence: CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Cas No.: 159519-65-0
Molecular Formula: C204H301N51O64
Molecular Weight: 4492
Purity (HPLC): 98.0%min.
Appearance: White to off-white amorphous solid
Single Impurity (HPLC): 0.5%max
Amino Acid Composition: ± 10% of theoretical
Peptide Content (N%): ≥ 80.0%
Water Content (Karl Fischer): ≤ 8.0%
TrifluoroAcetate Content(HPIC): ≤ 12.0%
MS (ESI): Consistent
Mass Balance: 95.0~105.0%
Grade: Pharmaceutical Grade
Storage: Closed, below 2 ~ 8º C preservation
Usage: Treatment option for patients suffering from HIV/AIDS

2. Description:

Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.

3. Application:

Enfuvirtide (INN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).